Keros Therapeutics Inc. (KROS) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Keros Therapeutics Inc. (KROS:NASDAQ), powered by AI.

Current Price
$10.03
Sector
Healthcare
What is the Keros Therapeutics Inc. stock price forecast?

Keros Therapeutics Inc. is currently trading at $10.03. View real-time AI analysis on Alpha Lenz.

What is Keros Therapeutics Inc. insider trading activity?

View the latest insider trading data for Keros Therapeutics Inc. on Alpha Lenz.

What is Keros Therapeutics Inc.'s P/E ratio?

View Keros Therapeutics Inc.'s valuation metrics on Alpha Lenz.

Keros Therapeutics Inc.

NASDAQ · KROS
$10.03-0.21(-2.05%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Keros Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Keros Therapeutics Inc.'s ROE is 19.9%. Explore profitability and growth together.

Ask for details

Company Overview

Keros Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of groundbreaking treatments for hematological and musculoskeletal disorders. The company's primary aim is to address unmet medical needs by advancing innovative therapies that target the transforming growth factor-beta (TGF-beta) family of proteins. These proteins play a critical role in the regulation of cellular growth and development, making them pivotal in treating a variety of severe diseases. Keros Therapeutics is deeply involved in research and development, with a strong pipeline of drug candidates aimed at conditions such as anemia and other blood-related disorders, as well as muscle diseases that impact patient mobility. By targeting these specific biological pathways, Keros is contributing significantly to the biopharmaceutical industry’s efforts in developing more effective and personalized medicine. The company's operations are an important part of the healthcare sector, striving to deliver breakthroughs that can enhance the quality of life for patients worldwide.

CEODr. Jasbir S. Seehra Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees148

Company Statistics

FY 2025

Profile

N/AMarket Cap
$244.06MRevenue
0.00Shares Out
148Employees

Margins

N/AGross
18.11%EBITDA
27.69%Operating
37.65%Pre-Tax
35.65%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

18.24%ROA
19.90%ROE
14.17%ROIC

Financial Health

$287.42MCash & Cash Equivalents
$-252.53MNet Debt
11.51%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Keros Therapeutics Inc. (ticker: KROS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 148 employees.

The current price is $10.03 with a P/E ratio of -x and P/B of -x.

ROE is 19.90% and operating margin is 27.69%. Annual revenue is $244M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Keros Therapeutics Inc. (KROS) Stock Forecast 2026 $10.03 — Price, Financials & Analyst Targets | Alpha Lenz